10 drug approvals to watch for in 2015
This article was originally published in Scrip
The FDA may have approved the highest number of new molecular entities for 18 years in 2014 (scripintelligence.com, 5 January 2015), but what should we expect for 2015? Here Scrip has taken a look at ten of the more interesting new products set for approval in the US and EU over the coming 12 months, in a rough order of when they are due:
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.